March 29, 2023 – FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada.
Read More from FACIT generates $1.5 billion in follow-on investment
March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.
Read More from CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer
February 21, 2023 – This year marks the 10th anniversary of the FACIT Falcons’ Fortunes pitch competition! Be part of the audience and watch the six finalists pitch their Ontario oncology innovations.
Read More from Registration is now open for FACIT Falcons’ Fortunes pitch competition and reception
December 5, 2022 – Your friends at FACIT wish you a healthy and relaxing holiday season. It has been a productive year and our team continues to grow the province’s biotech ecosystem through the commercialization of Ontario’s most promising cancer innovations.
Read More from Happy Holidays from the FACIT team!
September 28, 2022 – September 28, 2022 – FACIT congratulates Ontario-based start-ups Hyivy Health and HDAX Therapeutics as the latest recipients of capital through its Prospects Oncology Fund. Selected among a top-tier pool of applicants, these Ontario-based innovations illustrate excellent potential to benefit patients with cancer.
Read More from FACIT’s Prospects Fund fuels women’s health and brain cancer therapies for Ontario patients
June 16, 2022 – The paper “How to boost Ontario’s life sciences IP to help patients and the economy” discusses the importance of seed-stage investing and commercialization-venture partnerships to reap the benefits of taxpayers’ investment in post-secondary education and health research.
Read More from FACIT’s David O’Neill shares strategy for Ontario intellectual property
April 28, 2022 – April 27, 2022 – FACIT announced two recent strategic investments from its Prospects Oncology Fund in innovations arising from renowned cancer experts at the Ontario Institute for Cancer Research (OICR): Dr. Rima Al-awar, Head of Therapeutic Innovation and Drug Discovery, and Dr. Lincoln Stein, Head of Adaptive Oncology.
Read More from FACIT invests in OICR’s groundbreaking approaches to integrated drug discovery and cancer informatics
February 4, 2022 – February 4, 2022 – FACIT is pleased to announce the 2022 winner of its Falcons’ Fortunes pitch competition: Point Surgical Inc.. Point Surgical was founded as a joint venture between Toronto’s University Health Network, Unity Health Toronto and Light Matter Interaction Inc.
Read More from FACIT announces winner of 2022 Falcons’ Fortunes pitch competition on World Cancer Day
January 27, 2022 – January 27, 2022 – FACIT congratulates portfolio company Cellular Analytics on a recent publication by its CSO, Dr. Shana Kelley and collaborators, on the Company’s tumor-infiltrating lymphocyte (TIL) therapeutics platform.
Read More from High-potency TIL cell therapy approach reported using CytoFind platform developed by FACIT portfolio company Cellular Analytics
January 11, 2022 – Now in its 9th year, the FACIT Falcons’ Fortunes event is back for 2022! Be part of the audience and watch the six finalists pitch their Ontario oncology innovations.
Read More from Registration is now open for FACIT Falcons’ Fortunes virtual pitch competition